Home News About Us Contact Contributors Disclaimer Privacy Policy Help FAQ

Quick Search
My eDoc
Session History
Support Wiki
Direct access to
document ID:

          Institute: MPI für Herz- und Lungenforschung (W. G. Kerckhoff Institut)     Collection: Yearbook 2016     Display Documents

ID: 723936.0, MPI für Herz- und Lungenforschung (W. G. Kerckhoff Institut) / Yearbook 2016
[Medical treatment of pulmonary hypertension: what's new?]
Authors:Richter, M. J.; Gall, H.; Tello, K.; Sommer, N.; Seeger, W.; Grimminger, F.; Ghofrani, H. A.
Date of Publication (YYYY-MM-DD):2015-05
Title of Journal:Internist (Berl)
Issue / Number:5
Start Page:573
End Page:582
Audience:Not Specified
Abstract / Description:Pulmonary hypertension (PH) is a chronic progressive disease of the pulmonary circulation of multifactorial causes. The current diagnostic classification of PH distinguishes five main groups, which have as a common feature an increased pulmonary arterial pressure and pulmonary resistance. The classification differentiates pulmonary arterial hypertension (PAH), PH due to left heart disease, PH in lung diseases and/or hypoxia, chronic thromboembolic pulmonary hypertension (CTEPH), and PH with unclear/multifactorial mechanisms. Recent advances in basic research with the approval of new drugs and the establishment of therapeutic strategies, mainly in PAH and CTEPH, require a differentiated view of the disease, a careful diagnosis and initiation of therapy, and regular follow-ups. In this article, we provide an overview of the complex drug therapy currently available for PAH patients.
Free Keywords:Antihypertensive Agents/*administration & dosage; Endothelin Receptor Antagonists/*administration & dosage; Evidence-Based Medicine; Guanylate Cyclase; Humans; Hypertension, Pulmonary/diagnosis/*drug therapy; Phosphodiesterase 5 Inhibitors/*administration & dosage; Prostaglandins/*administration & dosage; Receptors, Cytoplasmic and Nuclear/*agonists; Treatment Outcome
External Publication Status:published
Document Type:Article
Communicated by:n.n.
Affiliations:MPI für physiologische und klinische Forschung
Identifiers:ISSN:1432-1289 (Electronic) 0020-9554 (Linking) %R 10.1007/s00108-015-3693-0 %(Medikamentose Therapie der pulmonalen Hypertonie: Was ist neu?
The scope and number of records on eDoc is subject to the collection policies defined by each institute - see "info" button in the collection browse view.